Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03635996 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
A Phase 3 study, sponsored by Milestone Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 169
- Enrollment target
NCT03635996 is a Phase 3 study that was terminated before completion, run by Milestone Pharmaceuticals. The registered enrollment target is 169 participants.
The verdict
NCT03635996, a Phase 3 study, was terminated before completion, sponsored by Milestone Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 169 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety of etripamil nasal spray (NS) 70 mg when self-administered by patients with an episode of Paroxysmal Supraventricular Tachycardia in an outpatient setting (i.e., without medical supervision).
Interventions
- DRUG Etripamil NS 70 mg
- DEVICE Aptar Pharma Nasal Spray Bidose System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2018-12-10 |
| Est. Completion | 2020-11-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03635996
The ClinicalTrials.gov registry entry for NCT03635996 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milestone Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Etripamil NS 70 mg is the first listed.
NCT03635996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03635996 about?
NCT03635996 is a clinical study titled "Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302". The primary objective of this study is to evaluate the safety of etripamil nasal spray (NS) 70 mg when self-administered by patients with an episode of Paroxysmal Supraventricular Tachycardia in an outpatient setting (i.e., without medical supervision).
What is the current status of trial NCT03635996?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 169 participants. The study started on 2018-12-10. Estimated completion is 2020-11-13.
What interventions are being tested in trial NCT03635996?
The interventions under investigation include: Etripamil NS 70 mg (DRUG), Aptar Pharma Nasal Spray Bidose System (DEVICE).
Who is sponsoring clinical trial NCT03635996?
This trial is sponsored by Milestone Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.